Updated Jul 7, 10:22 PM · 60 sources analyzed
Key Takeaways
Multiple large-pharma Phase 2/3 terminations today — Sanofi, Gilead, United Therapeutics, Keros — signal broad pipeline pruning with no disclosed outcome data.
Novartis NEPTUNUS-1 Sjögren's Phase 3 completion is the day's most consequential registry update; actual data disclosure is the only event that will matter for investors.
Syndax's revumenib solid-tumor termination is a cautionary signal for the menin inhibitor class outside hematology, where the mechanism remains unproven.
🏆 Winner
Novartis — NEPTUNUS-1 Phase 3 completion keeps ianalumab on track in an indication with zero approved disease-modifying therapies.
📉 Loser
United Therapeutics — Phase 3 termination of ralinepag removes a key next-generation PAH asset and raises pipeline replenishment questions.
🔭 Watch Next
Novartis ianalumab NEPTUNUS-1 efficacy data presentation, expected at ACR Convergence in November 2026, will be the first real test of whether a BAFF-receptor antibody can move the needle in Sjögren's syndrome.
Novartis ianalumab Phase 3 Sjögren's trial marked complete
Novartis's Phase 3 NEPTUNUS-1 trial of ianalumab (VAY736), a BAFF-receptor–targeting antibody, in active Sjögren's syndrome has been marked completed on ClinicalTrials.gov as of July 7, 2026. No efficacy or safety data have been released publicly from this registry update alone, meaning the completion signal is procedural rather than informative on outcomes. Sjögren's remains a condition with no approved disease-modifying therapy, so a Phase 3 readout from a well-powered Novartis trial — whenever it emerges — will be closely watched by rheumatology-focused investors and competing programs.
ClinicalTrials.gov ↗Keros Therapeutics
KER-012 in Pulmonary Arterial Hypertension (PAH)
The TROPOS Phase 2 study of KER-012 in PAH patients on background therapy has been marked as Terminated on ClinicalTrials.gov. No efficacy or safety data explaining the termination have been disclosed in this registry update.
Why it matters
A termination in Phase 2 without disclosed data is inherently ambiguous — it could reflect a business decision, safety signal, or futility — but any of those outcomes is a setback for a mid-cap biotech whose pipeline depth is under investor scrutiny. Keros will need to clarify the reason and reassure the market that its other programs are on track.
What to watch
Watch for Keros management commentary on the reason for TROPOS termination and any revised pipeline prioritization, likely at the next earnings call or investor conference.
United Therapeutics
Ralinepag in Pulmonary Arterial Hypertension (WHO Group 1)
The ADVANCE CAPACITY Phase 3 trial (ROR-PH-302), which was designed to assess ralinepag's effect on exercise capacity via peak oxygen consumption (VO2) by cardiopulmonary exercise testing, has been marked as Terminated on ClinicalTrials.gov. No outcome data are disclosed in this registry update.
Why it matters
United Therapeutics built its business on prostacyclin-pathway dominance, and ralinepag was positioned as a next-generation oral IP-receptor agonist to defend that turf. A Phase 3 termination — even without disclosed reasons — signals the company may struggle to organically refresh its PAH pipeline and could heighten pressure to pursue external business development.
What to watch
Watch for United Therapeutics to address the ADVANCE CAPACITY termination at the next investor event and to clarify whether any other ralinepag studies remain active or are being wound down.
Novartis Pharmaceuticals
Ianalumab (VAY736) in Active Sjögren's Syndrome
The NEPTUNUS-1 Phase 3 trial has been marked as Completed on ClinicalTrials.gov. Detailed efficacy and safety data have not yet been released; this is a registry status update only.
Why it matters
The registry completion flag tells us the trial finished enrolling and following patients, but nothing about whether ianalumab moved the needle on symptom burden or glandular function. Novartis will need to present primary endpoint data at a rheumatology congress or via press release before the competitive picture becomes clear — and rivals like UCB and AstraZeneca are watching closely.
What to watch
Watch for Novartis to present NEPTUNUS-1 efficacy data at ACR Convergence (expected November 2026) or via a standalone press release in the coming months.
Gilead Sciences
Obeldesivir (GS-5245) in Acute RSV Infection (nonhospitalized adults)
Gilead's Phase 2 study of obeldesivir — an oral antiviral being evaluated for RSV — has been marked as Terminated on ClinicalTrials.gov. No efficacy or safety data have been released in connection with this registry update.
Why it matters
Obeldesivir's RSV termination is unlikely to move Gilead's needle given its large portfolio, but it removes one pipeline option in a space where the company had been exploring expansion beyond HIV. The absence of a disclosed reason keeps the door slightly open for a pivoting strategy, but investors should treat this as a programmatic retreat until Gilead says otherwise.
What to watch
Watch for any Gilead pipeline update communication addressing obeldesivir's status across other indications, particularly mpox and influenza, where the compound has also been studied.
The NEPTUNUS-1 Phase 3 trial has been marked as Completed on ClinicalTrials.gov. Detailed efficacy and safety data have not yet been released; this is a registry status update only.
Why it matters
Sjögren's syndrome has no approved disease-modifying therapy, making any Phase 3 completion here a meaningful pipeline signal — but investors need actual data before updating models.
Analysis
The registry completion flag tells us the trial finished enrolling and following patients, but nothing about whether ianalumab moved the needle on symptom burden or glandular function. Novartis will need to present primary endpoint data at a rheumatology congress or via press release before the competitive picture becomes clear — and rivals like UCB and AstraZeneca are watching closely.
What to watch
Watch for Novartis to present NEPTUNUS-1 efficacy data at ACR Convergence (expected November 2026) or via a standalone press release in the coming months.
The TROPOS Phase 2 study of KER-012 in PAH patients on background therapy has been marked as Terminated on ClinicalTrials.gov. No efficacy or safety data explaining the termination have been disclosed in this registry update.
Why it matters
PAH is a crowded but high-value market; losing a Phase 2 asset narrows Keros's pipeline and raises questions about the activin signaling approach in this indication.
Analysis
A termination in Phase 2 without disclosed data is inherently ambiguous — it could reflect a business decision, safety signal, or futility — but any of those outcomes is a setback for a mid-cap biotech whose pipeline depth is under investor scrutiny. Keros will need to clarify the reason and reassure the market that its other programs are on track.
What to watch
Watch for Keros management commentary on the reason for TROPOS termination and any revised pipeline prioritization, likely at the next earnings call or investor conference.
Gilead's Phase 2 study of obeldesivir — an oral antiviral being evaluated for RSV — has been marked as Terminated on ClinicalTrials.gov. No efficacy or safety data have been released in connection with this registry update.
Why it matters
RSV antivirals for outpatients remain an unmet need, and a Phase 2 termination signals Gilead may be pulling back from this indication, ceding ground to other antivirals in development.
Analysis
Obeldesivir's RSV termination is unlikely to move Gilead's needle given its large portfolio, but it removes one pipeline option in a space where the company had been exploring expansion beyond HIV. The absence of a disclosed reason keeps the door slightly open for a pivoting strategy, but investors should treat this as a programmatic retreat until Gilead says otherwise.
What to watch
Watch for any Gilead pipeline update communication addressing obeldesivir's status across other indications, particularly mpox and influenza, where the compound has also been studied.
The ADVANCE CAPACITY Phase 3 trial (ROR-PH-302), which was designed to assess ralinepag's effect on exercise capacity via peak oxygen consumption (VO2) by cardiopulmonary exercise testing, has been marked as Terminated on ClinicalTrials.gov. No outcome data are disclosed in this registry update.
Why it matters
Ralinepag was United Therapeutics' bid to extend its PAH franchise beyond existing prostacyclin products; a Phase 3 termination in this indication is a meaningful pipeline setback for the company's long-term growth story.
Analysis
United Therapeutics built its business on prostacyclin-pathway dominance, and ralinepag was positioned as a next-generation oral IP-receptor agonist to defend that turf. A Phase 3 termination — even without disclosed reasons — signals the company may struggle to organically refresh its PAH pipeline and could heighten pressure to pursue external business development.
What to watch
Watch for United Therapeutics to address the ADVANCE CAPACITY termination at the next investor event and to clarify whether any other ralinepag studies remain active or are being wound down.
Sanofi's first-in-human Phase 1/2 study of SAR443579 — evaluated across relapsed or refractory AML, B-cell ALL, high-risk MDS, and blastic plasmacytoid dendritic cell neoplasm — has been marked as Terminated on ClinicalTrials.gov. No safety or efficacy data explaining the termination have been disclosed.
Why it matters
These are high-unmet-need hematologic malignancies with few approved options; a termination at Phase 1/2 suggests Sanofi is pruning its hematology pipeline, leaving space for competitors targeting similar blood cancers.
Analysis
SAR443579's termination across four indications simultaneously suggests a program-level decision rather than indication-specific futility, and Sanofi's hematology ambitions will need to be reassessed in light of this withdrawal. For smaller biotechs developing assets in R/R AML or B-ALL, this clears one large-pharma competitor from early-stage clinical space.
What to watch
Watch for Sanofi's next hematology pipeline update — likely at its annual R&D day — to understand whether this termination reflects a broader reprioritization away from blood cancers.
AstraZeneca completes Phase 2 of AZD2389 in liver fibrosis and compensated cirrhosis
AstraZeneca's Phase 2 study of AZD2389, evaluated for safety, tolerability, pharmacokinetics, and pharmacodynamic effects in patients with liver fibrosis and compensated cirrhosis, has been marked completed on ClinicalTrials.gov, though no data have been publicly released.
Why it matters
Liver fibrosis remains a large unmet need with no approved antifibrotic therapy; Phase 2 completion of a novel AstraZeneca compound suggests the field is attracting large-pharma investment and could yield a candidate for Phase 3 progression.
Analysis
AZD2389's mechanism has not been publicly disclosed, which makes competitive benchmarking difficult, but AstraZeneca's entry into liver fibrosis with a Phase 2 asset signals serious pipeline intent in a space where Madrigal's resmetirom holds the only approved therapy. The outcome of this Phase 2 will shape whether AstraZeneca pursues a larger program or exits.
What to watch
Watch for AstraZeneca to present AZD2389 pharmacodynamic and safety data at a liver disease congress such as AASLD (The Liver Meeting), likely in late 2026.
Takeda terminates TAK-280 first-in-human solid tumor study
Takeda's Phase 1/2 first-in-human study of TAK-280 in patients with unresectable locally advanced or metastatic solid tumors has been terminated, per ClinicalTrials.gov, with no safety or efficacy data disclosed.
Why it matters
Early-phase solid tumor programs carry high attrition, but terminations at first-in-human stage often reflect either safety signals or strategic portfolio rebalancing — either outcome informs how Takeda is managing its oncology pipeline footprint.
Analysis
Takeda has been actively reshaping its oncology portfolio, and TAK-280's termination adds to a pattern of selective pruning. Investors tracking Takeda's oncology strategy should note this alongside other pipeline decisions to gauge whether the company is narrowing its solid tumor ambitions or simply cutting early assets with insufficient differentiation.
What to watch
Watch for Takeda's next oncology pipeline disclosure — likely at ESMO 2026 or its R&D day — to see which solid tumor programs are being prioritized following this cut.
Syndax terminates revumenib expansion into colorectal cancer and solid tumors
Syndax Pharmaceuticals has terminated its Phase 1/2 study evaluating revumenib — a menin inhibitor (a drug that blocks a protein called menin, which drives certain leukemia-linked gene programs) already approved in leukemia — in colorectal cancer and other solid tumors, per ClinicalTrials.gov, without disclosing outcome data.
Why it matters
Revumenib's termination in solid tumors suggests menin inhibition may not translate readily beyond its validated hematologic niche, which is an important signal for the broader class of menin inhibitors now in development for non-blood cancers.
Analysis
For Syndax, this termination is strategically contained — revumenib's commercial story rests on hematologic malignancies, not solid tumors — but for competitors developing menin inhibitors with solid-tumor ambitions, this is an early cautionary data point worth noting. Investors should watch whether any of the larger menin inhibitor developers quietly adjust their indication strategies.
What to watch
Watch for Syndax's next data update on revumenib in its core leukemia indications at ASH 2026 to confirm the hematology franchise remains on track despite solid-tumor retrenchment.
Oral GLP-1 competing directly with Lilly and Novo. Best-in-class efficacy in Phase 2 at ~15% weight loss. Phase 3 success could make Viking an M&A target.
No coverage today
None of your tracked companies appeared in today's sources.